Pacific Edge Wins Prestigious INFINZ Investor Relations Award

Pacific Edge has been named as the winner of the NZX Emerging Leaders Best Investor Relations Award, at the prestigious INFINZ Awards dinner in Auckland on Tuesday night. The Award was open to all companies outside of the NZX20.

Judges said: “Pacific Edge clearly demonstrated alignment between its Investor Relations strategy and outcomes delivered, such as increased sell side coverage and conversion of interest to investment. During 2020, Pacific Edge kept the market informed as headlines came thick and fast taking advantage of the acceleration of Covid-19 trends - both for the company (telehealth) and in its engagement with shareholders/potential shareholders via increased virtual engagement. The combination of improved investor engagement and positive milestones for Pacific Edge has seen the company deliver excellent investor outcomes through 2020 with its share price re-rating strongly, liquidity improving and the number and diversity of shareholders increasing.”

On accepting the Award, CEO of Pacific Edge, David Darling, said: “Our approach to investor relations is to be timely, clear and transparent. It has been our goal to educate and inform the market about our high performance Cxbladder products, our strong market competitive advantage and the complex world of reimbursement for healthcare technology. Our innovative Cxbladder bladder cancer diagnostic tests are breaking new ground – they are disrupting the traditional testing regime for bladder cancer and providing new, better and more accurate ways for bladder cancer to be detected and managed. Our primary market is the USA, so not only is it important for us to inform investors about our diagnostic tests and how they work, we also need to educate them about how the physicians adopt new technology and how the US healthcare market pays for it.

“The people at Pacific Edge globally are very passionate about what they do and they share this passion with our investors, many of whom have been with us since the day we listed and have supported us on our journey. In the last 12 months, we’ve achieved some significant commercial milestones and our task now is to grow adoption and usage of our tests and deliver value for our shareholders. Pacific Edge has a very bright future.”